Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 12/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.45 |
| ▸ | BMX | P51813 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28189261 | 0.88 | NPC1 (0.57) | SYKNPC1RAB9AAURKAITK | |
| SCHEMBL17266536 | 0.83 | JAK3 (0.58) | SYKAURKA | |
| SCHEMBL28823474 | 0.81 | SYK (0.52) | SYKNPC1RAB9AAURKAITK | |
| SCHEMBL18780746 | 0.79 | AURKA (0.54) | SYKNPC1RAB9AAURKAAURKB | |
| SCHEMBL30737936 | 0.79 | AURKA (0.56) | NPC1RAB9AAURKAAURKB | |
| SCHEMBL18757745 | 0.78 | HDAC3 (0.48) | SYKAURKA | |
| SCHEMBL28850302 | 0.77 | SYK (0.50) | SYKNPC1RAB9AAURKAITK | |
| SCHEMBL28039312 | 0.75 | SYK (0.48) | SYKNPC1RAB9AAURKAITK | |
| SCHEMBL28039617 | 0.74 | SYK (0.48) | SYKNPC1RAB9AAURKAITK | |
| SCHEMBL26532197 | 0.74 | MEN1 (0.50) | SYKNPC1RAB9AAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | RIPK1, RIPK3, RIPK2 | SYK 2975/4885NPC1 925/4885RAB9A 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.